Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ANT308 PEG
- Development stage
- Preclinical
- Lead developer
- Cambium Oncology
- Modality
- Peptides
- Administration
- Subcutaneous
01
Overview
ANT308 PEG is a long-acting, PEGylated peptide antagonist of the vasoactive intestinal peptide (VIP) receptor. VIP is an immunosuppressive neuropeptide that is overexpressed in certain cancers, including acute myeloid leukemia (AML), where it functions as an alternative immune checkpoint. By inhibiting VIP receptor signaling, ANT308 PEG promotes T-cell activation, enhances the expression of effector markers such as Ki67 and TCF1, and increases the presence of chemokine receptors (CXCR3, CX3CR1) associated with tumor homing. In preclinical murine AML models, ANT308 PEG demonstrated superior anti-leukemia activity and improved survival compared to the non-PEGylated parent peptide, particularly when used in combination with PD-1 blockade.
- Other names
- PEGylated ANT308long-acting ANT308
02
Targets
VPAC (VIP receptor family)
Beyond the preview
Go deeper on ANT308 PEG.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ANT308 PEG.